2 Hot Wallstreet Cakes: Corcept Therapeutics Incorporated (NASDAQ:CORT), Exelixis, Inc. (NASDAQ:EXEL)

Corcept Therapeutics Incorporated (NASDAQ:CORT)

The shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) started off the last trading session with the price of $18.01 while closing the day with the price of $18.49. The shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) Rise 1.26% with the Gain of 0.48 points.

The shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) traded with the day volume of 2.26 Million shares whereas its average trading volume is 2.42 Million.

While analyzing the past performance of the stock we can see that the shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) Gain 6.26% in the last week while rising 18.83% in the last month. Past quarter performance shows the green light with 7.06%. The semi-annual and annual performance shows 3.82% and 86.77% respectively.

Some critical values of the shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) to be discussed here are: the beta which shows the value at 1.96 while Average True Range of Corcept Therapeutics Incorporated (NASDAQ:CORT) demonstrate the value at 0.95. The weekly and monthly volatility of the shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) are indicated at 4.76% and 5.71%. Also to discuss here is the Relative Strength Index or RSI which is depicted at 57.56.

While studying the financial position of the shares of Corcept Therapeutics Incorporated (NASDAQ:CORT), we can see that the Market capitalization of the company is at 2.06 Billion. The shares outstanding for the company is 111.5 Million and the shares float stands at 103.15 Million. The income of the company stand at 162.4 Million while the sales stand at 159.2 Million.

Here are some critical ratios for a financial perspective: Earnings Per Share or EPS of the company stand at 1.28, Price to Earnings or P/E is at 14.47, Price to Sales P/S show the value of 12.95, the Return on Asset ROA stood at 1.047 and the Return on Equity ROE depicted at 1.314 while Return on Investment ROI is at 0.85.


Exelixis, Inc. (NASDAQ:EXEL)

Exelixis, Inc. (NASDAQ:EXEL) started its previous trading session at $24.54 and closed at $23.81 showing a Fell of -3.37 Percent.

The Company traded with an average Volume of 2.89 Million whereas, its Day Volume stood at 2.26 Million.

Looking at the performance of the stock, Exelixis, Inc. (NASDAQ:EXEL) Loss -4.07% in the last week in its shares price and -20.05% in the last month. Quarterly performance shows a red of -8.25 Percent while Semi-Annual and Annual performances shows a -13.64 and 8.08 percent respectively.

Beta for Exelixis, Inc. (NASDAQ:EXEL) stands at 1.99 while the ATR (average true range) is at 1.04. The Stock’s Weekly and Monthly Volatility is 2.96% and 3.79% respectively showing a RSI value of 32.48.

While studying the financial position of the shares of Exelixis, Inc. (NASDAQ:EXEL), we can see that the Market capitalization of the company is at 7.08 Billion. The shares outstanding for the company is 297.18 Million and the shares float stands at 285.28 Million.

The Company generated an income of 154.2 Million and the sales of 452.5 Million in the Trailing Twelve Months period.

While analyzing the stock from technical aspects, Diluted Earnings per share stands at $0.49 a share. P/E (price to earnings) and P/S (price to sales) values are 48.2 and 15.64 respectively.

The Return on Assets stands at 0.26, ROE shows a value of 0.779 and ROI for Exelixis, Inc. (NASDAQ:EXEL) is 0.554 as of Trailing Twelve Months period.

The following two tabs change content below.

Eldred Matthew

Eldred Matthew covers Healthcare Sector Company recent Press Releases news updates. He has three year of experience in content writing as freelance writer. He performs analysis of Healthcare Companies and provides worthy information for investor community. He is an experienced writer with a precise grasp of the English language and a clear, compelling writing style.

View all contributions by

Eldred Matthew covers Healthcare Sector Company recent Press Releases news updates. He has three year of experience in content writing as freelance writer. He performs analysis of Healthcare Companies and provides worthy information for investor community. He is an experienced writer with a precise grasp of the English language and a clear, compelling writing style.

Leave a Comment